Payment overview · 2025
General Payments
$311.76
16 reported records · 9 companies
Healthcare provider profile · identity verified
Amy M. Carter, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NEW CASTLE, IN · NPI 1821179235
Verified facts
What the public records show
CMS Open Payments records show Amy M. Carter, M.D. received $311.76 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 642 claims for Eliquis by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 642 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.66 | 27.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.15 | 23.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $59.72 | 19.2% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.31 | 6.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.95 | 5.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.20 | 5.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.61 | 5.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.91 | 4.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.25 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $311.76 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $84.66 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $73.15 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $73.15 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $59.72 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 642 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
642 | 69 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
642 | 69 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1564 | 180 |
| Sertraline Hcl | Sertraline Hcl | 918 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 887 | 112 |
| Lisinopril | Lisinopril | 802 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 771 | 111 |
| Eliquis | Apixaban | 642 | 69 |
| Furosemide | Furosemide | 613 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 611 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 575 | 65 |
| Losartan Potassium | Losartan Potassium | 541 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 535 | 57 |
| Omeprazole | Omeprazole | 505 | 94 |
| Gabapentin | Gabapentin | 493 | 71 |
| Buspirone Hcl | Buspirone Hcl | 475 | 55 |
| Donepezil Hcl | Donepezil Hcl | 393 | 54 |
| Metformin Hcl | Metformin Hcl | 391 | 66 |
| Potassium Chloride | Potassium Chloride | 352 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 351 | 56 |
| Memantine Hcl | Memantine Hcl | 351 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 328 | 40 |
| Carvedilol | Carvedilol | 317 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 306 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 301 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 291 | 30 |
| Trazodone Hcl | Trazodone Hcl | 283 | 51 |
| Mirtazapine | Mirtazapine | 274 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 257 | 41 |
| Montelukast Sodium | Montelukast Sodium | 212 | 33 |
| Olanzapine | Olanzapine | 208 | 22 |
| Divalproex Sodium | Divalproex Sodium | 197 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 182 | 66 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 168 | 33 |
| Jardiance | Empagliflozin | 162 | 24 |
| Torsemide | Torsemide | 161 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 156 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 155 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 45 |
| Spironolactone | Spironolactone | 151 | 25 |
| Tramadol Hcl | Tramadol Hcl | 151 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 138 | 23 |
| Atenolol | Atenolol | 136 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 134 | 12 |
| Allopurinol | Allopurinol | 133 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 17 |
| Warfarin Sodium | Warfarin Sodium | 130 | suppressed |
| Famotidine | Famotidine | 122 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 115 | 12 |
| Nystatin | Nystatin | 114 | 56 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 113 | suppressed |
| Glipizide | Glipizide | 112 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 111 | 15 |
| Levetiracetam | Levetiracetam | 111 | suppressed |
| Simvastatin | Simvastatin | 107 | 29 |
| Ondansetron Odt | Ondansetron | 99 | 33 |
| Baclofen | Baclofen | 97 | suppressed |
| Loperamide | Loperamide Hcl | 95 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 22 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 89 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 16 |
| Trulicity | Dulaglutide | 83 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 80 | 12 |
| Prednisone | Prednisone | 78 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 15 |
| Cephalexin | Cephalexin | 75 | 43 |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | 12 |
| Latanoprost | Latanoprost | 74 | 15 |
| Pregabalin | Pregabalin | 73 | 13 |
| Rivastigmine | Rivastigmine | 73 | 20 |
| Clonazepam | Clonazepam | 72 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 71 | 21 |
| Bupropion Xl | Bupropion Hcl | 70 | 15 |
| Alendronate Sodium | Alendronate Sodium | 68 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 67 | suppressed |
| Risperidone | Risperidone | 67 | suppressed |
| Alprazolam | Alprazolam | 66 | suppressed |
| Ezetimibe | Ezetimibe | 66 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 23 |
| Glipizide Er | Glipizide | 63 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Brilinta | Ticagrelor | 51 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 14 |
| Primidone | Primidone | 51 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 49 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 49 | suppressed |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 48 | suppressed |
| Acyclovir | Acyclovir | 47 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 29 |
| Colestipol Hcl | Colestipol Hcl | 46 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 46 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 46 | 17 |
| Fentanyl | Fentanyl | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 43 | 43 |
| Methenamine Hippurate | Methenamine Hippurate | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Chlorthalidone | Chlorthalidone | 42 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Amoxicillin | Amoxicillin | 40 | 28 |
| Sucralfate | Sucralfate | 40 | suppressed |
| Amantadine | Amantadine Hcl | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | 12 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 25 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 36 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 12 |
| Meloxicam | Meloxicam | 36 | 12 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | 11 |
| Memantine Hcl Er | Memantine Hcl | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 30 | suppressed |
| Calcitriol | Calcitriol | 29 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 29 | 11 |
| Mirabegron Er | Mirabegron | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | 11 |
| Mupirocin | Mupirocin | 28 | 17 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Verapamil Sr | Verapamil Hcl | 24 | suppressed |
| Xifaxan | Rifaximin | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 17 |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Invokana | Canagliflozin | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 18 |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 11 |
| Aranesp | Darbepoetin Alfa In Polysorbat | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Dofetilide | Dofetilide | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Sulfasalazine | Sulfasalazine | 18 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 17 | suppressed |
| Nyamyc | Nystatin | 17 | 13 |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Budesonide Ec | Budesonide | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Exemestane | Exemestane | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $311.76 · 16 records | ABBVIE INC. | Auvelity, ELIQUIS, INGREZZA, INTELLIS ADAPTIVESTIM, NURTEC ODT, REXULTI, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error